Institutional Review Board, Hospital for Special Surgery
November 22, 2011
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
All patients undergoing primary total knee or hip arthroplasty with a hematocrit of 38 or less on preoperative testing. This will increase the likelihood that patients will require postoperative blood transfusions.
Patients with a hematocrit of greater than 38 at pre-operative testing and vulnerable populations such as minors, pregnant women, employees, prisoners, and the mental disabled.
Patients taking vasopressors and/or inotropic agents post-operatively
Stavros G. Memtsoudis, MD